Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy
Cancer Pathogenesis and Therapy · 2025-07 · 3 (4) · 309-321
DOI: 10.1016/j.cpt.2024.11.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Pathogenesis and Therapy, 2025-07. Verfasst von Uddalak Das und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plant Biotechnology, University of Agricultural Sciences, Bangalore, Karnataka, 560065, India. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Circular ribonucleic acid (circRNA) vaccines have emerged as a revolutionary strategy in cancer immunotherapy, facilitating novel approaches to induce robust and durable immune responses. Unlike traditional linear messenger RNA (mRNA) vaccines, circRNAs exhibit exceptional stability, enhanced translational efficiency, and resistance to exonuclease degradation, making them ideal candidates for vaccine development. This review delved into the fundamental principles underlying circRNA biology, highlighting their unique structural advantages and translational potential. We examined recent advancements in circRNA vaccine design, focusing on their application in oncology. As the circRNA-based cancer vaccine is a relatively novel technology, findings from all the major studies describing its efficacy were discussed. We further investigated their combination with other immunotherapeutic modalities, such as immune checkpoint inhibitors and adoptive cell therapies, that ensure the maximal anticancer effects of circRNA vaccines. Large-scale manufacturing, immunogenicity optimization, delivery systems, and other challenges and future directions in this field were also discussed. This study aims to thoroughly analyze the state-of-the-art and potential future applications of circRNA vaccines in cancer immunotherapy, highlighting them as exciting possibilities for next-generation cancer therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plant Biotechnology, University of Agricultural Sciences, Bangalore, Karnataka, 560065, India.
- Council of Scientific and Industrial Research (CSIR) - Centre for Cellular and Molecular Biology (CCMB), Hyderabad, Telangana, 500007, India.
- School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar, Odisha, 751024, India.
- Department of Zoology, Malabar Christian College, Kozhikode, Kerala, 673613, India.
- Department of Biosciences, JIS University, Kolkata, West Bengal, 700109, India.
- Department of Biotechnology and Bioinformatics, Sambalpur University, Burla, Odisha, 768019, India.
Zitieren
APA
Das, U., Banerjee, S., Sarkar, M., Muhammad L, F., Soni, T. K., Saha, M., Pradhan, G., & Chatterjee, B. (2025). Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy. Cancer Pathogenesis and Therapy, 3(4), 309-321. https://doi.org/10.1016/j.cpt.2024.11.003
Vancouver
Das U, Banerjee S, Sarkar M, Muhammad L F, Soni TK, Saha M, et al. Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy. Cancer Pathogenesis and Therapy. 2025;3(4):309-321. doi:10.1016/j.cpt.2024.11.003
BibTeX
@article{Das2025,
author = {Das, Uddalak and Banerjee, Soupayan and Sarkar, Meghna and Muhammad L, Fathah and Soni, Tanveen Kaur and Saha, Madhumita and Pradhan, Gayatri and Chatterjee, Bhaskarjyaa},
title = {Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy},
journal = {Cancer Pathogenesis and Therapy},
year = {2025},
volume = {3},
number = {4},
pages = {309--321},
doi = {10.1016/j.cpt.2024.11.003}
}
EUVIMED